JP2014511879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511879A5 JP2014511879A5 JP2014505370A JP2014505370A JP2014511879A5 JP 2014511879 A5 JP2014511879 A5 JP 2014511879A5 JP 2014505370 A JP2014505370 A JP 2014505370A JP 2014505370 A JP2014505370 A JP 2014505370A JP 2014511879 A5 JP2014511879 A5 JP 2014511879A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- disease
- vivo
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 82
- 210000004027 cell Anatomy 0.000 claims description 59
- 230000002757 inflammatory effect Effects 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 230000000626 neurodegenerative effect Effects 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 47
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 38
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 33
- 210000000068 Th17 cell Anatomy 0.000 claims description 32
- 239000012530 fluid Substances 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 29
- 108091008778 RORγ2 Proteins 0.000 claims description 28
- 210000003289 regulatory T cell Anatomy 0.000 claims description 28
- 210000000170 cell membrane Anatomy 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 23
- 230000006870 function Effects 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 11
- 230000001629 suppression Effects 0.000 claims description 11
- 230000033228 biological regulation Effects 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 230000003915 cell function Effects 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 7
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000004068 intracellular signaling Effects 0.000 claims description 7
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 229960001334 corticosteroids Drugs 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000002086 nanomaterial Substances 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000001578 tight junction Anatomy 0.000 claims description 6
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims description 5
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 5
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000038016 acute inflammation Diseases 0.000 claims description 4
- 230000006022 acute inflammation Effects 0.000 claims description 4
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 230000007000 age related cognitive decline Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 229960004436 budesonide Drugs 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 230000010287 polarization Effects 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 150000003431 steroids Chemical group 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010051288 Central nervous system inflammation Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 229960001888 ipratropium Drugs 0.000 claims description 3
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 3
- 150000002617 leukotrienes Chemical class 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 230000003959 neuroinflammation Effects 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 208000025698 brain inflammatory disease Diseases 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 210000002390 cell membrane structure Anatomy 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000001047 desmosome Anatomy 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 229960003776 glatiramer acetate Drugs 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000004692 intercellular junction Anatomy 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 229960005027 natalizumab Drugs 0.000 claims description 2
- 229960004398 nedocromil Drugs 0.000 claims description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 230000003614 tolerogenic effect Effects 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 2
- 229960005332 zileuton Drugs 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000002314 neuroinflammatory effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475119P | 2011-04-13 | 2011-04-13 | |
| US61/475,119 | 2011-04-13 | ||
| US201161497882P | 2011-06-16 | 2011-06-16 | |
| US61/497,882 | 2011-06-16 | ||
| PCT/US2012/033644 WO2012142501A1 (en) | 2011-04-13 | 2012-04-13 | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511879A JP2014511879A (ja) | 2014-05-19 |
| JP2014511879A5 true JP2014511879A5 (https=) | 2015-06-11 |
Family
ID=47006541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505370A Pending JP2014511879A (ja) | 2011-04-13 | 2012-04-13 | 炎症性神経変性疾患に関与するエフェクターｔ細胞を抑制および／または調節する組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120263764A1 (https=) |
| EP (1) | EP2696849A4 (https=) |
| JP (1) | JP2014511879A (https=) |
| KR (1) | KR20140020321A (https=) |
| CN (1) | CN103561722A (https=) |
| AU (1) | AU2012242592B2 (https=) |
| BR (1) | BR112013026064A2 (https=) |
| CA (1) | CA2831606A1 (https=) |
| CO (1) | CO6862101A2 (https=) |
| EA (1) | EA201391521A1 (https=) |
| IL (1) | IL228811A0 (https=) |
| MX (1) | MX2013011888A (https=) |
| WO (1) | WO2012142501A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
| US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| BR112012028540A2 (pt) | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| CA2917958A1 (en) * | 2013-07-23 | 2015-01-29 | Revalesio Corporation | Compositions and methods for upregulating hippocampal plasticity and hippocampus-dependent learning and memory |
| EP2905622A1 (en) * | 2014-02-07 | 2015-08-12 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnosis of a neurological disease |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| AU2016271292B2 (en) | 2015-06-03 | 2022-04-14 | The Medical College Of Wisconsin, Inc. | An engineered CCL20 locked dimer polypeptide |
| US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
| CN106399243B (zh) * | 2016-09-30 | 2019-09-20 | 深圳市再生之城生物医药技术有限公司 | 一种干细胞样记忆性t细胞体外诱导剂及方法 |
| CN107812004A (zh) * | 2017-11-24 | 2018-03-20 | 南京中医药大学 | 地氯雷他定及其药学上可接受的盐在制备治疗阿尔茨海默病的药物中的应用 |
| JP2021525796A (ja) * | 2018-05-25 | 2021-09-27 | レヴァレシオ・コーポレーション | 神経疾患の阻害 |
| EP3843673B1 (en) * | 2018-08-31 | 2026-04-15 | Revalesio Corporation | An oxygenated fluid for use for the treatment of stroke |
| CN113573778B (zh) * | 2018-11-16 | 2025-05-13 | 拉帕治疗有限公司 | 使用诱导性调节性T（iTREG）细胞进行的ALS治疗 |
| EP4076422A4 (en) | 2019-12-18 | 2024-01-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| CN113679719B (zh) * | 2021-08-17 | 2023-03-28 | 南京中医药大学 | 地氯雷他定及其盐在制备用于治疗运动功能障碍相关的神经退行性疾病的药物中的应用 |
| WO2023225021A1 (en) * | 2022-05-17 | 2023-11-23 | Curasen Therapeutics, Inc. | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) |
| WO2025015103A1 (en) * | 2023-07-10 | 2025-01-16 | The Children's Hospital Of Philadelphia | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology |
| WO2025123289A1 (zh) * | 2023-12-14 | 2025-06-19 | 深圳先进技术研究院 | 一种体外扩增原代细胞毒性t细胞亚群的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3213389A1 (de) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
| US20060116419A1 (en) * | 2002-12-06 | 2006-06-01 | Callahan James F | Nf-kb inhibitors |
| CN101291623B (zh) * | 2005-10-19 | 2010-12-15 | 皇家飞利浦电子股份有限公司 | X射线检查装置 |
| US9745567B2 (en) * | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US20100310609A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Compositions and methods for treatment of neurodegenerative diseases |
| US20100015235A1 (en) * | 2008-04-28 | 2010-01-21 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| WO2009062260A1 (en) * | 2007-11-15 | 2009-05-22 | David Richmond Booth | Therapy for multiple sclerosis |
| WO2009092087A2 (en) * | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| US8183040B2 (en) * | 2008-04-15 | 2012-05-22 | New York University | Methods for in vitro differentiation of Th-17+cells |
| AU2009241365B2 (en) * | 2008-04-28 | 2015-01-22 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| US20100166784A1 (en) * | 2008-12-30 | 2010-07-01 | The Washington University | Method and compositions for modulating th17 cell development |
| AU2010241736B2 (en) * | 2009-04-27 | 2016-01-28 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
-
2012
- 2012-04-13 US US13/446,844 patent/US20120263764A1/en not_active Abandoned
- 2012-04-13 MX MX2013011888A patent/MX2013011888A/es unknown
- 2012-04-13 CN CN201280026100.0A patent/CN103561722A/zh active Pending
- 2012-04-13 KR KR1020137029659A patent/KR20140020321A/ko not_active Withdrawn
- 2012-04-13 BR BR112013026064A patent/BR112013026064A2/pt not_active IP Right Cessation
- 2012-04-13 EA EA201391521A patent/EA201391521A1/ru unknown
- 2012-04-13 AU AU2012242592A patent/AU2012242592B2/en not_active Ceased
- 2012-04-13 CA CA2831606A patent/CA2831606A1/en not_active Abandoned
- 2012-04-13 WO PCT/US2012/033644 patent/WO2012142501A1/en not_active Ceased
- 2012-04-13 JP JP2014505370A patent/JP2014511879A/ja active Pending
- 2012-04-13 EP EP12770569.7A patent/EP2696849A4/en not_active Withdrawn
-
2013
- 2013-10-10 IL IL228811A patent/IL228811A0/en unknown
- 2013-11-12 CO CO13265808A patent/CO6862101A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511879A5 (https=) | ||
| JP2011523627A5 (https=) | ||
| JP2012506451A5 (https=) | ||
| JP2011500854A5 (https=) | ||
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| JP2012525396A5 (https=) | ||
| TWI784261B (zh) | 神經活性類固醇，其組合物及其用途 | |
| CN102257130B (zh) | 用于治疗胸腺基质淋巴细胞生成素(tslp)介导的病症的组合物和方法 | |
| JP2011500847A5 (https=) | ||
| JP6379113B2 (ja) | 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 | |
| CA2798127A1 (en) | Methods and compositions for protecting against neurotoxic agents | |
| CA2993478A1 (en) | Compositions and methods for immunomodulation | |
| NZ785712A (en) | Neuroactive steroids, compositions, and uses thereof | |
| Maillet et al. | Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization | |
| WO1994003598A1 (fr) | Agent antiallergique | |
| WO2019094679A1 (en) | BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs) | |
| TW200848071A (en) | Immunoglobulin fusion proteins and methods of making | |
| JP2012507995A (ja) | Ｈｌａ−ｇポリペプチドおよびその医薬的使用 | |
| US9821023B2 (en) | Methods for the treatment of central nervous system (CNS) disorders and mood disorders | |
| JP7244428B2 (ja) | Ｖｓｉｇ８ベースのキメラタンパク質 | |
| Yang et al. | Brain targeted lipid nanoparticles with Hv1 inhibitors alleviate neuroinflammation post-ischemic stroke | |
| CN113795269B (zh) | 血管活性肠肽(vip)拮抗剂的组合物和用途 | |
| JP2008500807A (ja) | 臨床応用のための融合タンパク質の塩基配列決定及び遺伝子発現 | |
| Galluzzi et al. | CARs on a highway with roadblocks | |
| Dézsi et al. | Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies |